rs1784692 — ZBTB16 ZBTB16/PLZF Ovarian Volume

ZBTB16 — A Retinoic Acid Gatekeeper in the Developing Follicle

Polycystic ovary syndrome is the most common endocrine disorder in women of reproductive age, affecting 8–13% globally, yet its genetic architecture has been assembled only slowly. The 2018 genome-wide meta-analysis by Day et al. added three new pieces to the puzzle, one of which sits in the ZBTB16¹¹ ZBTB16
zinc finger and BTB domain containing 16; also called PLZF (promyelocytic leukemia zinc finger); a transcriptional repressor of the POK family at chromosome 11q23.2 locus. The rs1784692-T allele reached genome-wide significance for PCOS susceptibility across 10,074 cases and 103,164 controls, and subsequent studies have connected the same locus to polycystic ovarian morphology — the ultrasound finding that anchors one of the three Rotterdam diagnostic criteria.

The Mechanism

ZBTB16/PLZF is a transcriptional repressor discovered through its role in a chromosomal translocation, t(11;17)(q23;q21), that fuses it to the retinoic acid receptor alpha (RARα) in a rare subtype of acute promyelocytic leukemia. This translocation introduced PLZF into cancer biology, but the gene's normal function is broader: it orchestrates cell cycle arrest, differentiation, and tissue-specific development in multiple compartments, including the reproductive system.

In the ovary, the connection operates through two converging pathways. First, PLZF is an androgen-responsive gene — its expression is regulated by the same androgenic milieu that characterises the PCOS follicular microenvironment. Second, TGF-β signalling during fetal ovarian development directly suppresses ZBTB16 expression in ovarian fibroblasts: Azumah et al. 2022²² Azumah et al. 2022
TGFβ regulates PCOS candidate genes in the bovine fetal ovary. Human Reproduction 37:1252–1267 showed that TGFβ1 significantly downregulates ZBTB16 among a cluster of PCOS candidate genes in fetal ovarian somatic cells, while TGF-β inhibition upregulates the same genes — suggesting that the PCOS susceptibility haplotype at this locus influences the developmental TGF-β set point that shapes ovarian architecture before birth.

The rs1784692 variant lies within an intron of ZBTB16 and does not change the protein. Its effect is regulatory — the T allele likely tags a haplotype that alters ZBTB16 expression in follicular somatic cells, shifting the balance of cell cycle regulation and androgen responsiveness in granulosa and theca cell populations.

The Evidence

The primary genetic evidence comes from the largest PCOS GWAS in European ancestry at the time of its publication. Day et al. 2018³³ Day et al. 2018
Large-scale genome-wide meta-analysis of PCOS suggests shared genetic architecture for different diagnosis criteria. PLoS Genet 14:e1007813 combined 10,074 PCOS cases and 103,164 controls and identified ZBTB16 as one of three novel loci, with rs1784692-T reaching p=2×10⁻¹⁰ and a beta of 0.1438. The genetic architecture was consistent across PCOS defined by NIH criteria (anovulation + hyperandrogenism), Rotterdam criteria (broader), and self-report, indicating the ZBTB16 locus contributes to the core shared biology rather than to diagnostic artefacts.

Replication in a Chinese cohort supported the same direction of effect: Yang et al. 2020⁴⁴ Yang et al. 2020
Verification of a ZBTB16 variant in polycystic ovary syndrome patients. Reprod Biomed Online 41:735–743 enrolled 526 PCOS cases and 522 controls (Han Chinese women) and found the minor C allele protective against PCOS (OR 0.556, 95% CI 0.408–0.759, p=1.83×10⁻⁴, adjusted for BMI and age). Within the PCOS group, CC+CT carriers had higher BMI and lower LH than TT carriers — suggesting the protective allele may modulate the metabolic-reproductive interface of the syndrome.

The phenotypic connection to ovarian morphology was established by Tidwell et al. 2024⁵⁵ Tidwell et al. 2024
Phenotypes associated with PCOS risk variants. J Endocr Soc 9:bvae208 in 404 European PCOS cases and 408 controls: ZBTB16 reached p<0.001 for association with ovarian morphology — polycystic ovary appearance on ultrasound — placing this locus among the three strongest morphological signal carriers alongside SHBG and CYP3A7/CYP3A51. A parallel replication in 497 Indian women (Dadachanji et al. 2024⁶⁶ Dadachanji et al. 2024) found rs1784692 associated with reduced PCOS susceptibility specifically in lean women, with the protective allele correlating with lower insulin, better insulin sensitivity, lower LH:FSH ratio, and higher ApoA1 — a metabolic-reproductive signature consistent with improved granulosa cell function.

Practical Actions

The ZBTB16 locus tags susceptibility to polycystic ovarian morphology — the ultrasound finding of increased antral follicle count and enlarged ovarian volume that reflects follicular arrest. Unlike DENND1A (which drives androgen excess) or LHCGR (which alters gonadotropin receptor sensitivity), the ZBTB16 mechanism appears to operate earlier in follicular development, making it particularly relevant to the morphological subtype of PCOS that may present without severe hyperandrogenism.

Monitoring should focus on ovarian morphology assessment alongside standard PCOS hormonal markers. Myo-inositol and D-chiro-inositol support FSH signalling in the granulosa cells whose development ZBTB16 helps orchestrate. Because the protective allele in the Indian cohort correlated with better insulin sensitivity and lipid profile, metabolic surveillance (fasting insulin, HOMA-IR, lipid panel) is valuable even in lean women with this locus.

Interactions

The ZBTB16 locus acts independently of the DENND1A (rs7852296) and THADA/LHCGR loci that are also represented in the PCOS genetic architecture. Day et al. 2018 identified all three novel loci (PLGRKT, ZBTB16, MAPRE1) as independent signals alongside the 11 previously established PCOS loci. The combined polygenic burden from DENND1A (androgen excess mechanism), ZBTB16 (follicular morphology mechanism), and LHCGR (gonadotropin sensitivity mechanism) represents distinct biological pathways that, in aggregate, determine individual PCOS phenotype severity and subtype. Women carrying risk alleles at both rs7852296 (DENND1A) and rs1784692 (ZBTB16) may present with both elevated androgens and polycystic morphology — the combined Rotterdam-criteria profile most relevant for fertility treatment planning.